Lipid metabolism in patients with chronic hepatitis C, non-alcoholic fatty liver disease and obesity under the influence of treatment
In: Mìžnarodnij Endokrinologìčnij Žurnal, Jg. 20 (2024), Heft 2, S. 93-98
Online
academicJournal
Zugriff:
Background. In patients with advanced stages of liver fibrosis, progression of liver fibrosis and obesity may be observed after complete elimination of hepatitis C virus. The aim of the research was to study the impact of antiviral therapy on lipid metabolism indicators in patients with chronic hepatitis C (CHC) combined with non-alcoholic fatty liver disease (NAFLD). Materials and methods. Eighty-two patients were under observation, 56 with CHC combined with NAFLD and 26 with CHC. They were divided into three groups: first one (n = 23) — patients with CHC with NAFLD and obesity, second (n = 33) — participants with CHC, NAFLD and overweight, third group (n = 26) — CHC patients with normal body weight. All patients underwent determination of blood lipid spectrum and cytokines Ang-2, TGF-β1, TNF-α and neopterin, IL-6. The degree of liver fibrosis and steatosis was determined using FibroMax. Patients received sofosbuvir 400 mg, daclatasvir 60 mg once a day for 12 weeks. Results. The study found that 8 patients had liver fibrosis F3–4, 11 people — F2–3, 23 — F1–2, and 37 people — F0–1. Sustained virological response was achieved in 95.1 % of patients with CHC. No response was received in 4.9 % of patients who had advanced stages of liver fibrosis and obesity or increased body weight. After the treatment, a slight increase in the level of high-density lipoprotein cholesterol was registered in 61.1 % of patients in group 3, 50 % in group 2, and only in 31.2 % of patients in group 1. Content of total cholesterol tended to increase in patients of groups 1 and 2 and remained unchanged in group 3. Although the changes in the levels of low- and very low-density lipoprotein were statistically significant, they were not large in terms of absolute values. In 62.5 % of CHC patients with concomitant NAFLD who had obesity or increased body weight and F3–4 fibrosis, even after complete elimination of the virus, the levels of Ang-2 and TGF-β1 remain high and positively correlate with the degree of steatosis and the stage of liver fibrosis. Conclusions. After the successful elimination of the hepatitis C virus, lipid metabolism disorders are registered in patients with concomitant non-alcoholic fatty liver disease, F3–4 fibrosis and increased body weight
Titel: |
Lipid metabolism in patients with chronic hepatitis C, non-alcoholic fatty liver disease and obesity under the influence of treatment
|
---|---|
Autor/in / Beteiligte Person: | Derbak, M.A. ; Lizanets, N.V. ; Hanych, O.T. ; Mashura, V.V. ; Mashura, H.Y. ; Ustych, O.V. ; Rostoka, L.M. |
Link: | |
Zeitschrift: | Mìžnarodnij Endokrinologìčnij Žurnal, Jg. 20 (2024), Heft 2, S. 93-98 |
Veröffentlichung: | Zaslavsky O.Yu., 2024 |
Medientyp: | academicJournal |
ISSN: | 2224-0721 (print) ; 2307-1427 (print) |
DOI: | 10.22141/2224-0721.20.2.2024.1369 |
Schlagwort: |
|
Sonstiges: |
|